Skip to main content
2026 CRT Conference Main banner

CRT 2026

Joint Session

Session:: CRT | ISCTR 2026 Session | Opportunities for Cardiovascular Translational Research in 2026 | What Changed? [Non-CME]

Panel Discussion

Sunday, March 8, 2026
1:03 PM - 1:30 PM EST
Location: Monroe

    Moderator(s)

  • Spencer B. King, III, MD, MACC, MSCAI

    Professor of Medicine Emeritus
    Emory University
    Atlanta, Georgia, United States

    Disclosure(s): No financial relationships to disclose

  • Charles A. Simonton, MD, FACC, FSCAI

    EVP Chief Medical Advisor
    Abiomed a Johnson + Johnson MedTech Company
    Charlotte, North Carolina, United States

    Disclosure(s): Abiomed / Johnson & Johnson: Employee (Ongoing)

    • Panel Discussant(s)

  • Anthony DeMaria, MD

    Judy and Jack White Chair in Cardiology
    University of California, San Diego
    La Jolla, California, United States

    Disclosure(s): Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Grant/Research Support (Ongoing)

  • Chip Hance, BS, MBA

    CEO
    Regatta Medical
    Bannockburn, Illinois, United States

    Disclosure(s): No financial relationships to disclose

  • Tamara Syrek Jensen, JD

    Consultant
    Rubrum Advising

    Disclosure(s): No financial relationships to disclose

  • John C. Laschinger, MD

    SVP Corporate Development
    Edwards Lifesciences
    lutherville, Maryland, United States

    Disclosure(s): Edwards Lifesciences LLC: Employee (Ongoing), Stock Options [in privately held companies] (Ongoing), Stock-privately held company (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

  • Joon Lee, MD

    Chief Executive Officer
    Emory Healthcare

    Disclosure(s): No financial relationships to disclose

  • Stanton J. Rowe, PhD

    CEO
    Nidus Biomedical
    Irvine, California, United States

    Disclosure(s): No financial relationships to disclose

  • Ken Stein, MD

    Senior Vice President and Chief Medical Officer
    Boston Scientific
    St.Paul, Minnesota, United States

    Disclosure(s): Boston Scietific: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

  • Bram Zuckerman, MD

    Director Office of CV Devices
    U.S. Food and Drug Administration
    Silver Spring, Maryland, United States

    Disclosure(s): No financial relationships to disclose

Disclosure(s):
Spencer B. King, MD, MACC, MSCAI, III: No financial relationships to disclose
Charles A. Simonton, MD, FACC, FSCAI: Abiomed / Johnson & Johnson: Employee (Ongoing)
Anthony DeMaria, MD: Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Grant/Research Support (Ongoing)
Chip Hance, BS, MBA: No financial relationships to disclose
Tamara Syrek Jensen, JD: No financial relationships to disclose
John C. Laschinger, MD: Edwards Lifesciences LLC: Employee (Ongoing), Stock Options [in privately held companies] (Ongoing), Stock-privately held company (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Joon Lee, MD: No financial relationships to disclose
Stanton J. Rowe, PhD: No financial relationships to disclose
Ken Stein, MD: Boston Scietific: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Bram Zuckerman, MD: No financial relationships to disclose